Japan CAR-T Cell Therapy Market to be dominated by Hospitals through 2029

High incidence of hematological cancers and rising healthcare expenditure are driving Japan CAR-T Cell Therapy Market in the forecast period 2025-2029.

According to TechSci Research report, “CAR-T Cell Therapy Market – Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2019-2029”, the Japan CAR-T Cell Therapy Market stood at USD66.06 Million in 2023 and is anticipated to register a high CAGR of 13.44% during the forecast period. Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has demonstrated a proactive approach in facilitating the development and commercialization of innovative therapies. The agency has put in place expedited review pathways for regenerative medicine products, which includes CAR-T cell therapies. These pathways aim to expedite the development and approval process for therapies that address unmet medical needs, enabling faster market entry and access to innovative treatments. Further, Japan boasts a robust research ecosystem that includes academia, government institutions, and industry players. Collaborative efforts between these entities have played a pivotal role in advancing CAR-T cell therapy research.

Such partnerships promote knowledge exchange, accelerate clinical trials, and enhance the understanding of cellular immunotherapies, thereby fostering a conducive environment for the growth of the CAR-T cell therapy market. The Japanese government has taken strides to bolster its biotechnology sector, recognizing its potential to drive innovation and economic growth. Financial incentives and supportive policies have encouraged investment in biotech companies engaged in CAR-T cell therapy research and development. This influx of investment not only fuels advancements in treatment but also propels the commercialization of these therapies, benefiting both patients and the economy. In addition, as more patients receive CAR-T cell therapy, healthcare providers gain valuable experience in managing its unique challenges and adverse events. This growing clinical expertise reduces uncertainties associated with adopting the therapy, making it more accessible and attractive to both healthcare professionals and patients, leading to the expansion of the market.

One of the primary challenges faced by the CAR-T cell therapy market in Japan pertains to the complex regulatory landscape and reimbursement mechanisms. Developing and commercializing CAR-T therapies involves navigating stringent regulatory requirements, including clinical trial approvals and manufacturing standards. The lengthy and intricate approval processes can delay the introduction of new therapies to the market, stalling patients' access to potentially life-saving treatments.

Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on "Japan CAR-T Cell Therapy Market”

The Japan CAR-T Cell Therapy Market segmentation is based on Product Type, Tumor Type, Indication, Treatment Type, Targeted Antigen, End User, Company, and Region.

Based on Product Type, the market is divided into Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others. The Yescarta segment is expected to witness a rise over the forecast period. Yescarta demonstrated significant clinical efficacy in clinical trials. It showed remarkable response rates and durable remissions in patients with relapsed or refractory DLBCL who had exhausted other treatment options. Also, the CAR design used in Yescarta is thought to contribute to its efficacy. The CAR is designed to target the CD19 protein, which is commonly expressed on the surface of B-cell lymphomas. This specific targeting helps the CAR-T cells recognize and attack the cancer cells.

Based on Tumor Type, the market is divided into Hematological Malignancies, Solid Tumors. The Hematological Malignancies segment is expected to witness a rise over the forecast period. Some types of hematological malignancies, like certain types of leukemia and lymphoma, can have a genetic component. If there are certain genetic mutations or predispositions that are more common in the Japanese population, it might contribute to a higher incidence of these malignancies.

Based on Indication, the market is divided into Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others. The Diffused Large B-Cell Lymphoma (DLBCL) segment is anticipated to grow at a faster rate during the forecast period. This is attributed to the rising approvals of CAR-T Cell Therapy and the increasing prevalence of Diffused Large B-Cell Lymphoma in Japan.

Based on Treatment Type, the market is divided into Single Treatment and Combination Treatment. The Combination Treatment segment is anticipated to grow at a faster rate during the forecast period. The rationale behind combination therapy is to exploit different pathways and mechanisms of action to enhance treatment outcomes, minimize resistance, and broaden the scope of cancers that can be targeted.

Based on Targeted Antigen, the market is divided into CD 19, BCMA (B-Cell Maturation Antigen), Others. The BCMA (B-Cell Maturation Antigen) segment is anticipated to grow at a faster rate during the forecast period. BCMA CAR-T cell therapy is a specialized form of CAR-T cell therapy designed to target cancer cells that express BCMA, such as those found in multiple myeloma. The process begins with the collection of the patient's T cells through a process called leukapheresis. These T cells are then genetically modified in a laboratory to express the BCMA-targeting CAR on their surface.

Based on End User, the market is divided into Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others. The Hospital segment is anticipated to grow at a faster rate during the forecast period. This can be attributed to the presence of advanced technology, skilled personnel, and certified medical experts. As a result, there has been a rise in the confidence patients have in the hospital, leading to a boost in market expansion during the projected timeframe.

Some of the major companies operating in the Japan CAR-T Cell Therapy Market include:

• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Johnson & Johnson KK
• Bristol-Myers Squibb
• Gilead Sciences
  
  

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“Hokkaido boasts a cluster of world-class research institutions and universities that have heavily invested in the field of cellular therapy. Institutions such as Hokkaido University, Sapporo Medical University, and the Advanced Institute for Materials Research have been at the forefront of CAR-T cell therapy research, contributing significantly to advancements in the field. Hokkaido-based institutions have formed strategic partnerships with both domestic and international organizations, enabling them to leverage resources, expertise, and funding. Collaborations with pharmaceutical giants, biotech startups, and academic institutions have accelerated the development and commercialization of CAR-T cell therapies and is expected to contribute to a remarkable growth of the Japan CAR-T Cell Therapy Market in the forecast period," said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

Japan CAR-T Cell Therapy Market, By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others), By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others), By Treatment Type (Single Treatment, Combination Treatment), By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others) By Region, Competition, Forecast & Opportunities, 2019-2029F.has evaluated the future growth potential of Japan CAR-T Cell Therapy Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Japan CAR-T Cell Therapy Market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Web:  https://www.techsciresearch.com